New Data Demonstrate Aimovig™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies
Go back to New Data Demonstrate Aimovig™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies| Amgen Inc (NASDAQ: AMGN) | Delayed: 401.00 -36.23 (8.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $437.23 | 52 Week High | $176.85 | |||
| Open | $408.90 | 52 Week Low | $133.64 | |||
| Day High | $410.03 | P/E | 60.39 | |||
| Day Low | $399.68 | EPS | $6.64 | |||
| Volume | 1,157,205 | |||||

